Evaxion Retains Global Rights to EVX-B2 After MSD Declines Option
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 19 2025
0mins
Should l Buy EVAX?
Source: Globenewswire
- Change in Partnership Opportunity: MSD's decision not to exercise its option for Evaxion's Gonorrhea vaccine candidate EVX-B2 allows Evaxion to seek new licensing partners while retaining global rights to the project, although this decision does not impact its cash runway.
- Vaccine Potential: EVX-B2 has demonstrated protective effects against Gonorrhea in preclinical studies, highlighting the potential of Evaxion's AI-Immunology™ platform to develop vaccines that address significant unmet medical needs, despite the absence of approved vaccines to date.
- Financial Stability: Evaxion's cash flow outlook did not include a potential in-licensing of EVX-B2 by MSD, meaning this decision will not affect its cash runway, which is projected to extend into the second half of 2027, ensuring financial flexibility for future R&D activities.
- R&D Direction: Evaxion is also developing an mRNA version of EVX-B2 in collaboration with Afrigen Biologics, further expanding its vaccine pipeline and demonstrating the company's ongoing innovation capabilities in addressing infectious diseases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EVAX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EVAX
Wall Street analysts forecast EVAX stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.170
Low
10.00
Averages
12.33
High
16.00
Current: 3.170
Low
10.00
Averages
12.33
High
16.00
About EVAX
Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Evaxion to Report 2025 Financial Results on March 5
- Financial Report Release: Evaxion A/S will release its 2025 financial results on March 5, 2026, before the Nasdaq opens, aiming to provide investors with the latest financial status and business updates.
- Management Conference Call: On the same day at 14:30 CET/08:30 EST, Evaxion's executive team will host a conference call and webcast to present the financial results and answer investor questions, enhancing engagement with stakeholders.
- Platform Advantage: Evaxion's AI-Immunology™ platform leverages artificial intelligence to decode the human immune system, focusing on developing innovative vaccines for cancer and infectious diseases, showcasing its leading position in the biotech sector.
- Clinical Pipeline Development: The company has established a clinical pipeline of personalized and off-the-shelf cancer vaccine candidates, reflecting its commitment to addressing high unmet medical needs and aiming to improve patient quality of life.
See More
Evaxion Looks for New Partner for Gonorrhea Vaccine Following Merck's Withdrawal
Merck's Decision on EVX-B2: Merck & Co. has opted not to pursue Evaxion's gonorrhea vaccine candidate EVX-B2, allowing Evaxion to retain global rights and seek other licensing partners.
Gonorrhea Vaccine Landscape: Despite affecting over 80 million people annually, no gonorrhea vaccine has been approved yet, although preclinical studies show promise for EVX-B2.
Evaxion's Financial Outlook: Evaxion's CEO stated that Merck's decision does not impact their financial projections, which extend to the second half of 2027.
Recent Developments: Evaxion has successfully out-licensed another vaccine candidate, EVX-B3, to Merck, receiving an upfront payment and potential future milestone payments, while the FDA recently approved GSK's oral treatment for gonorrhea.
See More
Evaxion Retains Global Rights to EVX-B2 After MSD Declines Option
- Change in Partnership Opportunity: MSD's decision not to exercise its option for Evaxion's Gonorrhea vaccine candidate EVX-B2 allows Evaxion to seek new licensing partners while retaining global rights to the project, although this decision does not impact its cash runway.
- Vaccine Potential: EVX-B2 has demonstrated protective effects against Gonorrhea in preclinical studies, highlighting the potential of Evaxion's AI-Immunology™ platform to develop vaccines that address significant unmet medical needs, despite the absence of approved vaccines to date.
- Financial Stability: Evaxion's cash flow outlook did not include a potential in-licensing of EVX-B2 by MSD, meaning this decision will not affect its cash runway, which is projected to extend into the second half of 2027, ensuring financial flexibility for future R&D activities.
- R&D Direction: Evaxion is also developing an mRNA version of EVX-B2 in collaboration with Afrigen Biologics, further expanding its vaccine pipeline and demonstrating the company's ongoing innovation capabilities in addressing infectious diseases.
See More
Evaxion Retains Global Rights to EVX-B2 After MSD Declines Option
- Change in Partnership Opportunities: MSD's decision not to exercise its option for Evaxion's Gonorrhea vaccine candidate EVX-B2 allows Evaxion to seek new partners while retaining global rights, although this decision does not impact its cash flow outlook.
- Vaccine Potential: EVX-B2 has demonstrated protective effects against Gonorrhea in preclinical studies, and despite the absence of an approved vaccine, its success could address a significant unmet medical need, enhancing Evaxion's position in vaccine development.
- Financial Stability: Evaxion's cash runway remains unaffected by MSD's decision, extending into the second half of 2027, which ensures continued investment in vaccine development without immediate financial pressure.
- Technological Innovation: Evaxion is also developing an mRNA version of EVX-B2 in collaboration with Afrigen Biologics, further expanding its vaccine candidate pipeline and showcasing its technological capabilities and market adaptability under the AI-Immunology™ platform.
See More
Evaxion Unveils EVX-04 Cancer Vaccine, Significantly Inhibiting Tumor Growth
- Vaccine Development Progress: Evaxion's EVX-04 vaccine successfully induces specific T-cell responses and effectively inhibits tumor growth in preclinical models, demonstrating its potential to improve treatment options for acute myeloid leukemia (AML) patients.
- Broad Antigen Coverage: The vaccine identifies and selects 16 non-conventional endogenous retrovirus (ERV) tumor antigen fragments through the AI-Immunology™ platform, ensuring broad coverage across different patients' tumors, thereby enhancing the likelihood of immune recognition.
- Market Demand Alignment: As AML is characterized by high mortality rates and limited existing treatment options, the introduction of EVX-04 not only addresses the urgent need for new therapies but also presents significant commercial opportunities for Evaxion.
- Innovative Technology Application: The
See More
Evaxion Unveils EVX-04 Cancer Vaccine, Prevents Tumor Growth
- Robust Immune Response: Evaxion's EVX-04 cancer vaccine successfully induces specific T-cell responses and significantly prevents tumor growth in preclinical models, indicating its potential value for acute myeloid leukemia (AML) patients.
- Broad Applicability: Developed using the AI-Immunology™ platform, the vaccine targets non-conventional endogenous retrovirus (ERV) tumor antigens, ensuring extensive tumor coverage and applicability across various hard-to-treat cancers, addressing the urgent market need for new therapies.
- Data-Driven Target Selection: By analyzing genomic data from AML patients, EVX-04 selects 16 optimal ERV antigen fragments from five million, ensuring immune recognition and enhancing therapeutic efficacy.
- Immediate Use Vaccine Concept: As an off-the-shelf vaccine, EVX-04 is ready for immediate administration post-diagnosis, aiming to improve treatment options for AML patients and meet the significant unmet medical needs in current treatment modalities.
See More
Evaxion to Report 2025 Financial Results on March 5
- Financial Report Release: Evaxion A/S will release its 2025 financial results on March 5, 2026, before the Nasdaq opens, aiming to provide investors with the latest financial status and business updates.
- Management Conference Call: On the same day at 14:30 CET/08:30 EST, Evaxion's executive team will host a conference call and webcast to present the financial results and answer investor questions, enhancing engagement with stakeholders.
- Platform Advantage: Evaxion's AI-Immunology™ platform leverages artificial intelligence to decode the human immune system, focusing on developing innovative vaccines for cancer and infectious diseases, showcasing its leading position in the biotech sector.
- Clinical Pipeline Development: The company has established a clinical pipeline of personalized and off-the-shelf cancer vaccine candidates, reflecting its commitment to addressing high unmet medical needs and aiming to improve patient quality of life.
See More
Evaxion Looks for New Partner for Gonorrhea Vaccine Following Merck's Withdrawal
Merck's Decision on EVX-B2: Merck & Co. has opted not to pursue Evaxion's gonorrhea vaccine candidate EVX-B2, allowing Evaxion to retain global rights and seek other licensing partners.
Gonorrhea Vaccine Landscape: Despite affecting over 80 million people annually, no gonorrhea vaccine has been approved yet, although preclinical studies show promise for EVX-B2.
Evaxion's Financial Outlook: Evaxion's CEO stated that Merck's decision does not impact their financial projections, which extend to the second half of 2027.
Recent Developments: Evaxion has successfully out-licensed another vaccine candidate, EVX-B3, to Merck, receiving an upfront payment and potential future milestone payments, while the FDA recently approved GSK's oral treatment for gonorrhea.
See More
Evaxion Retains Global Rights to EVX-B2 After MSD Declines Option
- Change in Partnership Opportunity: MSD's decision not to exercise its option for Evaxion's Gonorrhea vaccine candidate EVX-B2 allows Evaxion to seek new licensing partners while retaining global rights to the project, although this decision does not impact its cash runway.
- Vaccine Potential: EVX-B2 has demonstrated protective effects against Gonorrhea in preclinical studies, highlighting the potential of Evaxion's AI-Immunology™ platform to develop vaccines that address significant unmet medical needs, despite the absence of approved vaccines to date.
- Financial Stability: Evaxion's cash flow outlook did not include a potential in-licensing of EVX-B2 by MSD, meaning this decision will not affect its cash runway, which is projected to extend into the second half of 2027, ensuring financial flexibility for future R&D activities.
- R&D Direction: Evaxion is also developing an mRNA version of EVX-B2 in collaboration with Afrigen Biologics, further expanding its vaccine pipeline and demonstrating the company's ongoing innovation capabilities in addressing infectious diseases.
See More
Evaxion Retains Global Rights to EVX-B2 After MSD Declines Option
- Change in Partnership Opportunities: MSD's decision not to exercise its option for Evaxion's Gonorrhea vaccine candidate EVX-B2 allows Evaxion to seek new partners while retaining global rights, although this decision does not impact its cash flow outlook.
- Vaccine Potential: EVX-B2 has demonstrated protective effects against Gonorrhea in preclinical studies, and despite the absence of an approved vaccine, its success could address a significant unmet medical need, enhancing Evaxion's position in vaccine development.
- Financial Stability: Evaxion's cash runway remains unaffected by MSD's decision, extending into the second half of 2027, which ensures continued investment in vaccine development without immediate financial pressure.
- Technological Innovation: Evaxion is also developing an mRNA version of EVX-B2 in collaboration with Afrigen Biologics, further expanding its vaccine candidate pipeline and showcasing its technological capabilities and market adaptability under the AI-Immunology™ platform.
See More
Evaxion Unveils EVX-04 Cancer Vaccine, Significantly Inhibiting Tumor Growth
- Vaccine Development Progress: Evaxion's EVX-04 vaccine successfully induces specific T-cell responses and effectively inhibits tumor growth in preclinical models, demonstrating its potential to improve treatment options for acute myeloid leukemia (AML) patients.
- Broad Antigen Coverage: The vaccine identifies and selects 16 non-conventional endogenous retrovirus (ERV) tumor antigen fragments through the AI-Immunology™ platform, ensuring broad coverage across different patients' tumors, thereby enhancing the likelihood of immune recognition.
- Market Demand Alignment: As AML is characterized by high mortality rates and limited existing treatment options, the introduction of EVX-04 not only addresses the urgent need for new therapies but also presents significant commercial opportunities for Evaxion.
- Innovative Technology Application: The
See More
Evaxion Unveils EVX-04 Cancer Vaccine, Prevents Tumor Growth
- Robust Immune Response: Evaxion's EVX-04 cancer vaccine successfully induces specific T-cell responses and significantly prevents tumor growth in preclinical models, indicating its potential value for acute myeloid leukemia (AML) patients.
- Broad Applicability: Developed using the AI-Immunology™ platform, the vaccine targets non-conventional endogenous retrovirus (ERV) tumor antigens, ensuring extensive tumor coverage and applicability across various hard-to-treat cancers, addressing the urgent market need for new therapies.
- Data-Driven Target Selection: By analyzing genomic data from AML patients, EVX-04 selects 16 optimal ERV antigen fragments from five million, ensuring immune recognition and enhancing therapeutic efficacy.
- Immediate Use Vaccine Concept: As an off-the-shelf vaccine, EVX-04 is ready for immediate administration post-diagnosis, aiming to improve treatment options for AML patients and meet the significant unmet medical needs in current treatment modalities.
See More
